Participants in this study have been diagnosed with cancer and have advanced nonfunctional neuroendocrine tumors. This is a voluntary study to find out if the drug everolimus (Afinitor®) is sage and has beneficial effects in people who have this disease. About 279 patients will join in this study at around 120 research clinics in several countries around the world.
Deb Pearson, 319-356-4797
Participants in this study have been diagnosed with aggressive B-Cell lymphoma. The purpose of this research study is to compare the good and/or bad effects of an experimental approach to treating the disease. Approximately 9 people will take part in this study conducted by investigators at the University of Iowa. Involvement in the chemotherapy regimen, may last between 9 to 24 weeks. After completing the study treatment portion, the study doctor will ask participants to schedule follow-up exams for at least 5 years.
Clarine Halvorsen, 319-356-3944
Participants in this research study have sarcoma that has spread or recurred. The purpose of this research study is to find out what effects, good and/or bad, an experimental drug called MLN8237 has on participants and their sarcoma.
MLN8237 is a new investigational drug currently being tested for treatment of sarcoma. This study is approved and sponsored by the National Cancer Institute (NCI). An investigational drug is a medication that has not been approved for use by the U.S. Food and Drug Administration (FDA). The drug is only available in a clinical trial.
Approximately 15 people will take part in this study conducted by investigators at the University of Iowa. Up to 135 subjects will take part in this study at serveral cancer centers nationwide. This includes up to about 30 subjects at Memorial Sloan-Kettering Cancer Center.
Janan Geick-Miller, 319-356-3944
Participants in this study have been diagnosed with Mantle Cell Lymphoma (MCL), which has been previously treated and the disease has returned. The purpose of the study is to assess the effects (both good and bad) of Ibrutinib in MCL and whether the MCL responds to treatment. The Study treatment is a maximum of 3 years, depending on how well the participant responds to treatment.
Mary Schall 319-356-3516
Participants in this study have been diagnosed with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). There are two treatment groups, one will receive the study drug called ibrutinib and the second group will receive a placebo. The purpose of the study is to assess the effects (both good and bad) of ibrutinib in patients with CLL or SLL and whether the CLL or SLL responds to this treatment.
Mary Schall, 319-356-3516
Copyright © 2013 The University of Iowa. All Rights Reserved.